亚洲精品国产情侣AV在线,日韩精品一区二区三区色欲AV,免费看高清黄A级毛片

  • <object id="jwsct"><legend id="jwsct"></legend></object>
    <object id="jwsct"></object>
  • <s id="jwsct"></s>
      1. 血管內皮生長因子受體1(VEGFR1)檢測試劑盒(酶聯免疫吸附試驗法)

        ELISA Kit for Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)

        Flt1; Fms-Related Tyrosine Kinase 1; Vascular Permeability Factor Receptor; Fms-like tyrosine kinase 1; Tyrosine-protein kinase receptor FLT

        • 血管內皮生長因子受體1(VEGFR1)檢測試劑盒(酶聯免疫吸附試驗法) 產品包裝(模擬)
        • 血管內皮生長因子受體1(VEGFR1)檢測試劑盒(酶聯免疫吸附試驗法) 產品包裝(模擬)
        • 血管內皮生長因子受體1(VEGFR1)檢測試劑盒(酶聯免疫吸附試驗法) 實驗結果圖
        • SEB818Mu.jpg 標準曲線圖
        • Certificate 通過ISO 9001、ISO 13485質量體系認證

        特異性

        本試劑盒用于檢測血管內皮生長因子受體1(VEGFR1),經檢測與其它相似物質無明顯交叉反應。
        由于受到技術及樣本來源的限制,不可能完成對所有相關或相似物質交叉反應檢測,因此本試劑盒有可能與未經檢測的其它物質有交叉反應。

        回收率

        分別于定值血清及血漿樣本中加入一定量的血管內皮生長因子受體1(VEGFR1)(加標樣品),重復測定并計算其均值,回收率為測定值與理論值的比率。

        樣本 回收率范圍(%) 平均回收率(%)
        serum(n=5) 87-95 90
        EDTA plasma(n=5) 95-103 98
        heparin plasma(n=5) 94-105 97

        精密度

        精密度用樣品測定值的變異系數CV表示。CV(%) = SD/mean×100
        批內差:取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續測定20 次,分別計算不同濃度樣本的平均值及SD值。
        批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定,每個樣本使用同一試劑盒重復測定8次,分別計算不同濃度樣本的平均值及SD值。
        批內差: CV<10%
        批間差: CV<12%

        線性

        在定值血清及血漿樣本內加入適量的血管內皮生長因子受體1(VEGFR1),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中血管內皮生長因子受體1(VEGFR1)含量的測定值與理論值的比率。

        樣本 1:2 1:4 1:8 1:16
        serum(n=5) 98-105% 93-102% 86-97% 91-101%
        EDTA plasma(n=5) 84-102% 78-94% 81-96% 84-101%
        heparin plasma(n=5) 78-102% 79-91% 87-95% 97-105%

        穩定性

        經測定,試劑盒在有效期內按推薦溫度保存,其活性降低率小于5%。
        為減小外部因素對試劑盒破壞前后檢測值的影響,實驗室的環境條件需盡量保持一致,尤其是實驗室內溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。

        實驗流程

        1. 實驗前標準品、試劑及樣本的準備;
        2. 加樣(標準品及樣本)100µL,37°C孵育1小時;
        3. 吸棄,加檢測溶液A100µL,37°C孵育1小時;
        4. 洗板3次;
        5. 加檢測溶液B100µL,37°C孵育30分鐘;
        6. 洗板5次;
        7. 加TMB底物90µL,37°C孵育10-20分鐘;
        8. 加終止液50µL,立即450nm讀數。

        實驗原理

        將血管內皮生長因子受體1(VEGFR1)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標準品或標本,其中的血管內皮生長因子受體1(VEGFR1)與連接于固相載體上的抗體結合,然后加入生物素化的血管內皮生長因子受體1(VEGFR1)抗體,將未結合的生物素化抗體洗凈后,加入HRP標記的親和素,再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉化成藍色,并在酸的作用下轉化成最終的黃色。顏色的深淺和樣品中的血管內皮生長因子受體1(VEGFR1)呈正相關。用酶標儀在450nm波長下測定吸光度(O.D.值),計算樣品濃度。

        相關產品

        編號 適用物種:Mus musculus (Mouse,小鼠) 應用(僅供研究使用,不用于臨床診斷!)
        RPB818Mu02 血管內皮生長因子受體1(VEGFR1)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
        RPB818Mu01 血管內皮生長因子受體1(VEGFR1)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
        PAB818Mu01 血管內皮生長因子受體1(VEGFR1)多克隆抗體 WB; IHC; ICC; IP.
        PAB818Mu02 血管內皮生長因子受體1(VEGFR1)多克隆抗體 WB; IHC; ICC; IP.
        LAB818Mu71 血管內皮生長因子受體1(VEGFR1)多克隆抗體(生物素標記) WB; IHC; ICC.
        SEB818Mu 血管內皮生長因子受體1(VEGFR1)檢測試劑盒(酶聯免疫吸附試驗法) Enzyme-linked immunosorbent assay for Antigen Detection.
        SCB818Mu 血管內皮生長因子受體1(VEGFR1)檢測試劑盒(化學發光免疫分析法) Chemiluminescent immunoassay for Antigen Detection.
        LMB818Mu 血管內皮生長因子受體1(VEGFR1)單因子檢測試劑盒(流式熒光發光法) Magnetic Luminex Assay for Antigen Detection.

        參考文獻

        雜志 參考文獻
        Clinical cardiology Growth Differentiation Factor 15 and Coronary Collateral Formation [PubMed: 20014173]
        Microvascular Research Mutant hypoxia inducible factor-1α improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle [PubMed: 20937289]
        Science Alert Antiangiogenic Activities of Cinnamon, Black and Green Tea Extracts on Experimentally Induced Breast Cancer in Rats [Scialert: Source]
        Acta Biomater Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study [PubMed: 26689470]
        Naunyn Schmiedebergs Arch Pharmacol The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis [PubMed: 26269412]
        Acta Biomaterialia Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study [Pubmed:26689470]
        Journal?of?Cellular?Physiology A?Human?3D?In?Vitro?Model?to?Assess?the?Relationship?Between?Osteoporosis?and?Disseminationto?Bone?of?Breast?Cancer?Tumor?Cells. [pubmed:27925188]
        Oncotarget Fasudil attenuates soluble fms-like tyrosine kinase-1 (sFlt-1)-induced hypertension in pregnant mice through RhoA/ROCK pathway. [pubmed:29262624]
        Placenta Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. [pubmed:28962687]
        Acta?Biomaterialia Synergistic effect of Si-hydroxyapatite coating and VEGF adsorption on Ti6Al4V-ELI scaffolds for bone regeneration in an osteoporotic bone environment [Pubmed: 30445158]
        Scientific Reports Association between Upper-airway Surgery and Ameliorative Risk Markers of endothelial function in obstructive Sleep Apnea [Pubmed: 31882827]
        JOURNAL OF DERMATOLOGICAL TREATMENT Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris [Pubmed: 32043381]
        FASEB JOURNAL Cyclin G2 upregulation impairs migration, invasion, and network formation through RNF123/Dvl2/JNK signaling in the trophoblast cell line HTR8/SVneo, a possible?… [Pubmed: 33205477]
        Children (Basel) sFlt-1/PlGF Ratio in Prediction of Short-Term Neonatal Outcome of Small for Gestational Age Neonates [34438609]
        Oxid Med Cell Longev Reactive Oxygen Species are Essential for Placental Angiogenesis During Early Gestation [Pubmed:35693704]
        留言咨詢
        亚洲精品国产情侣AV在线,日韩精品一区二区三区色欲AV,免费看高清黄A级毛片